{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:43:07Z","timestamp":1740184987646,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007210","name":"RWTH Aachen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007210","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Ein 73-j\u00e4hriger Mann mit vorbekannter demenzieller Entwicklung wurde mit Hypernatri\u00e4mie bei Volumendepletion aufgenommen. Urs\u00e4chlich daf\u00fcr zeigte sich eine neue neurogene Schluckst\u00f6rung, bei Z.\u202fn. mehreren Schlaganf\u00e4llen bestand eine Halbseitensymptomatik. Bei der Sichtung der Unterlagen vorangegangener Krankenhausaufenthalte fiel wiederholt eine verl\u00e4ngerte aPTT (aktivierte partielle Thromboplastinzeit) auf; bereits f\u00fcnf Jahre zuvor bestand ambulant der Verdacht auf ein Antiphospholipidantik\u00f6rpersyndrom (APS), ohne dass die Diagnostik komplettiert worden w\u00e4re. Wir haben die Diagnose eines prim\u00e4ren APS gestellt und eine Antikoagulation mit Vitamin-K-Antagonisten und ASS (Acetylsalicyls\u00e4ure) begonnen.<\/jats:p>","DOI":"10.1007\/s00108-023-01581-3","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T08:02:31Z","timestamp":1695196951000},"page":"402-406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Geriatrischer Patient mit neurologischer Symptomatik und verl\u00e4ngerter aPTT","Geriatric patient with neurological symptoms and prolonged aPTT"],"prefix":"10.1007","volume":"65","author":[{"given":"Aisuluu","family":"Atakanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Heiligers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius","family":"Bollheimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Fleig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"1581_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis\u00a0S et\u00a0al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J\u00a0Thromb Haemost 4:295\u2013306. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01753.x","journal-title":"J Thromb Haemost"},{"key":"1581_CR2","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMc1808253","volume":"379","author":"D Garcia","year":"2018","unstructured":"Garcia\u00a0D, Erkan\u00a0D (2018) Diagnosis and management of the antiphospholipid syndrome. N\u00a0Engl J Med 379:1290. https:\/\/doi.org\/10.1056\/NEJMc1808253","journal-title":"N Engl J Med"},{"key":"1581_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1177\/0961203309106832","volume":"18","author":"R Cervera","year":"2009","unstructured":"Cervera\u00a0R, Boffa\u00a0MC, Khamashta\u00a0MA, Hughes\u00a0GR (2009) The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 18:889\u2013893. https:\/\/doi.org\/10.1177\/0961203309106832","journal-title":"Lupus"},{"key":"1581_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/1756-185x.12494","volume":"18","author":"Y Cherif","year":"2015","unstructured":"Cherif\u00a0Y et al (2015) Late-onset primary antiphospholipid syndrome in the elderly: a\u00a0report of seven cases. Int J Rheum Dis 18:103\u2013107. https:\/\/doi.org\/10.1111\/1756-185x.12494","journal-title":"Int J Rheum Dis"},{"key":"1581_CR5","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/rheumatology\/key437","volume":"58","author":"F Grimaud","year":"2019","unstructured":"Grimaud\u00a0F et\u00a0al (2019) Clinical and immunological features of antiphospholipid syndrome in the elderly: a\u00a0retrospective national multicentre study. Rheumatology 58:1006\u20131010. https:\/\/doi.org\/10.1093\/rheumatology\/key437","journal-title":"Rheumatology"},{"key":"1581_CR6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","volume":"74","author":"R Cervera","year":"2015","unstructured":"Cervera\u00a0R et al (2015) Morbidity and mortality in the antiphospholipid syndrome during a\u00a010-year period: a\u00a0multicentre prospective study of 1000 patients. Ann Rheum Dis 74:1011\u20131018. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204838","journal-title":"Ann Rheum Dis"},{"key":"1581_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1055\/s-0038-1648840","volume":"72","author":"P Vila","year":"1994","unstructured":"Vila\u00a0P, Hernandez\u00a0MC, Lopez-Fernandez\u00a0MF, Batlle\u00a0J (1994) Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 72:209\u2013213","journal-title":"Thromb Haemost"},{"key":"1581_CR8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","volume":"78","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou\u00a0MG et\u00a0al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78:1296\u20131304. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215213","journal-title":"Ann Rheum Dis"},{"key":"1581_CR9","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo\u00a0V et al (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132:1365\u20131371. https:\/\/doi.org\/10.1182\/blood-2018-04-848333","journal-title":"Blood"},{"key":"1581_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.autrev.2018.04.009","volume":"17","author":"V Dufrost","year":"2018","unstructured":"Dufrost\u00a0V et al (2018) Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 17:1011\u20131021. https:\/\/doi.org\/10.1016\/j.autrev.2018.04.009","journal-title":"Autoimmun Rev"},{"key":"1581_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3233\/JAD-181294","volume":"69","author":"T Bucci","year":"2019","unstructured":"Bucci\u00a0T et\u00a0al (2019) Relationship of antiphospholipid antibodies to risk of dementia: a\u00a0systematic review. J\u00a0Alzheimers Dis 69:561\u2013576. https:\/\/doi.org\/10.3233\/JAD-181294","journal-title":"J Alzheimers Dis"},{"key":"1581_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11910-021-01124-z","volume":"21","author":"LM Rato","year":"2021","unstructured":"Rato\u00a0LM, Bandeira\u00a0M, Romao\u00a0VC, Aguiar de Sousa\u00a0D (2021) Neurologic manifestations of the antiphospholipid syndrome\u2014an update. Curr Neurol Neurosci Rep 21:41. https:\/\/doi.org\/10.1007\/s11910-021-01124-z","journal-title":"Curr Neurol Neurosci Rep"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01581-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:04:13Z","timestamp":1711105453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01581-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1581"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01581-3","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"8 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Atakanova, A.\u00a0Heiligers, M.\u00a0Kirschner, C.\u00a0Bollheimer und S.\u00a0Fleig geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}